Abstract
Human papillomavirus (HPV) infection, primarily HPV16, is responsible for a substantial increase in the incidence of oropharyngeal cancers (base of tongue, tonsil, soft palate, and pharyngeal wall) among men in recent years in several developed countries [1]. Recent studies have discovered HPV16 E6 seropositivity (IgG antibodies measured through a Luminex-multiplexed assay) as a biomarker strongly associated with prospective oropharyngeal cancer risk [2,3]. Yet, little is known regarding HPV16 E6 seroepidemiology in the general population.
Highlights
Human papillomavirus (HPV) infection, primarily HPV16, is responsible for a substantial increase in the incidence of oropharyngeal cancers (base of tongue, tonsil, soft palate, and pharyngeal wall) among men in recent years in several developed countries [1]
Human papillomavirus (HPV) infection, primarily HPV16, is responsible for a substantial increase in the incidence of oropharyngeal cancers among men in recent years in several developed countries [1]
The key results include: 1) low prevalence of HPV16 E6 seropositivity (~0.8%); 2) seropositivity was associated with several markers of high-risk sexual behaviours; and 3) seropositivity was not associated with age, gender, or smoking status
Summary
Human papillomavirus (HPV) infection, primarily HPV16, is responsible for a substantial increase in the incidence of oropharyngeal cancers (base of tongue, tonsil, soft palate, and pharyngeal wall) among men in recent years in several developed countries [1]. HPV16 E6 antibodies appear to mark persistence of oral/oropharyngeal HPV infections, given that population-level E6 seropositivity is low relative to oral HPV16 incidence (~1% annual incidence) [8].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call